Since the introduction of plasma exchange as a treatment for GuillainBarre syndrome (GBS) patients, treatment related fluctuations have been found to occur in about 10% of the patients. These fluctuations are considered additional evidence of the beneficial effect of plasma exchange. In this report the occurrence of such treatment related fluctuations is described in the 147 patients who took part in the Dutch Guillain-Barre trial comparing high dose intravenous immunoglobulin with plasma exchange. Six of 72 patients in the plasma exchange group and eight of 74 in the immunoglobulin group showed such fluctuation. These results support the biological effect of immunoglobulin. More general use of immunoglobulin should await the full analysis of the Dutch GBS trial which is in progress.
In Guillain-Barre syndrome (GBS) , relapses occur in about 1-6% of the patients, after a symptom free interval of months or years. Many of these relapsing patients were suffering from a chronic inflammatory demyelinating polyneuropathy (CIDP). In a retrospective study of the natural history of the GBS in 68 consecutive patients we observed no relapses during a follow up period ranging from two to 14 years. 7 Several trials have recently established the beneficial effect of plasma exchange (PE)."9
Since the wider application of this treatment, early relapses have been shown to occur in patients with an initially good response.' 10" Osterman described six patients (out of a series of 37 of whom 23 responded to PE) who deteriorated again two to four weeks after completing PE.'0 In Ropper's series, 10 (14), demonstrating a relapsing and remitting course, the initial diagnosis had to be changed its, treatment from GBS to CIDP, the onset of which may in 10% (95% sometimes be subacute."5 This patient now f 73 patients in successfully receives chronic therapy, with patients in the smaller doses of IgIV at regular intervals, as has t in the IgIV been reported previously.'""8
These fluctuaNot all patients with secondary deterioration the disease and need additional treatment. We saw four They should patients who improved spontaneously followiturally occur-ing their relapse, confirming the observations of ter months or Ropper."1 There was no difference between these and the other patients; they showed a esults of both comparable clinical course with those patients eported secon-who received a second course of treatment. At ie fluctuations present, however, it is not possible to tell in PE, are con-advance how long deterioration will proceed iological effec-and therefore it is difficult to withhold a second rovide further treatment if a patient has responded well and is f several trials again showing deterioration. Wehavenow
In conclusion, the earlier report,12 suggesting )ccurs alike in a beneficial response to IgIV in GBS, is supporeither PE or ted by this study on treatment related fluctuat--imilar therapy ing course in some GBS patients following reatments in-IgIV. This is an important, independent, restion that the observation to confirm the biological efficacy of [gIV might be IgIV. This study further supports the preliminary positive results of the Dutch a response to Guillain-Barre trial. Initial analysis of the main the. pathogen-outcome criterion has shown that IgIV comsed by PE or pares favourably with PE.'9 At present a full I after therapy. analysis ofthis trial is in progress. This analysis nly a minority should be awaited before deciding to apply ;e patients are IgIV routinely in GBS patients. 
